Merck & Co Inc is moving to the forefront of Alzheimer's disease research by starting a mid-stage study of a drug from a new class of oral medicines that aim to shut down production of a protein associated with the disease. The Phase II trial, which will compare the drug with a placebo, is a global, multi-center study that includes a group of 200 to test safety. The study is expected to eventually enroll up to 1,700 patients in the main Phase III Trial.
This study looks like it's a great example of an experiment. It has a placebo group (control group) and a group with the drug. I think if this experiment goes well, it will have excellent reliability and validity and move to the third stage of the trial.